Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02865-4 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Hideki Goto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo-shi, Hokkaido, 060-8648, Japan. hidekigt0220@gmail.com. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) face a poor prognosis in the absence of effective treatment options. Ibrutinib plus venetoclax demonstrated high response rates and a tolerable safety profile in the primary analysis of the Phase 2, M20-075 study (NCT04477486) in Japanese patients with R/R MCL. We report updated efficacy and safety from this study with longer follow-up.
Methods
Patients received 560 mg ibrutinib and 400 mg venetoclax (5-week ramp-up to 400 mg) once daily for up to 104 weeks followed by ibrutinib monotherapy. Primary endpoint was Independent Review Committee-assessed complete response (CR) rate. Secondary endpoints included overall response rate (ORR), duration of response (DOR), undetectable minimal residual disease (uMRD) in patients achieving CR, progression-free survival (PFS), overall survival (OS), and safety.
Results
After a median follow-up of 37.2 months, 13 patients had received ibrutinib plus venetoclax, 8 (62%) remained on ibrutinib monotherapy, and 9 (69%) completed 24 months of venetoclax. ORR was 83% (10/12 [per-protocol population]; all CR); median DOR was not reached. All 6 patients positive for MRD at baseline who achieved CR had uMRD. Median PFS and OS were not reached. Most frequent Grade ≥ 3 treatment-emergent adverse events (TEAEs) were neutropenia (46%) and leukopenia (23%); one TEAE leading to treatment discontinuation was squamous cell carcinoma unrelated to treatment. There were no cases of tumor lysis syndrome or TEAEs leading to death.
Conclusion
Long-term follow-up of ibrutinib plus venetoclax showed prolonged efficacy and a well-tolerated safety profile in Japanese patients with R/R MCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo-shi, Hokkaido, 060-8648, Japan. hidekigt0220@gmail.com.
- Yamagata University Hospital, Yamagata, Japan.
- Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
- Tohoku University Hospital, Miyagi, Japan.
- Kyushu University Hospital, Fukuoka, Japan.
Zitieren
APA
Goto, H., Ito, S., Kizaki, M., Yamaguchi, M., Fukuhara, N., Kato, K., Saito, T., Terui, Y., Soshin, T., Satomi-Tsushita, N., Honda, H., Qian, C., & Izutsu, K. (2025). Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02865-4
Vancouver
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, et al. Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02865-4
BibTeX
@article{Goto2025,
author = {Goto, Hideki and Ito, Satoshi and Kizaki, Masahiro and Yamaguchi, Masaki and Fukuhara, Noriko and Kato, Koji and Saito, Toko and Terui, Yasuhito and Soshin, Tomomi and Satomi-Tsushita, Natsuko and Honda, Hideyuki and Qian, Chen and Izutsu, Koji},
title = {Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02865-4}
}
EUVIMED